Savara (SVRA) Stock Price, News & Analysis

Company Overview

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing. Molgramostim has been evaluated in clinical studies, including the Phase 3 IMPALA-2 program.

Headquartered in Austin, Texas, Savara conducts its research and clinical development activities internationally. The company was formerly known as Savara Pharmaceuticals and has focused its strategy on advancing treatments for rare pulmonary diseases. Savara is led by Matthew Pauls, who serves as president and chief executive officer.

Key Stats

• Today's Range: $4.13 to $4.58
• 50-Day Range: $4.22 to $5.61
• 52-Week Range: $3.86 to $7.01
• Volume: 2.83 million shs
• Average Volume: 2.70 million shs
• Market Capitalization: $867.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.25
• Consensus Rating: Moderate Buy

Savara Stock Analysis - MarketRank™

Savara scored higher than 40% of companies evaluated by MarketBeat, and ranked 656th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Savara has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Savara has a consensus price target of $10.25, representing about 142.9% upside from its current price of $4.22.

Amount of Analyst Coverage

Savara has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Savara are expected to grow in the coming year, from ($0.66) to ($0.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Savara is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Savara is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Savara has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.39% of the float of Savara has been sold short.

Short Interest Ratio / Days to Cover

Savara has a short interest ratio ("days to cover") of 17.24, which indicates bearish sentiment.

Change versus previous month

Short interest in Savara has recently increased by 0.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Savara does not currently pay a dividend.

Dividend Growth

Savara does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.13

News Sentiment

Savara has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Savara this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

9 people have added Savara to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Savara insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of Savara is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SVRA
• Previous Symbol: AMEX:ANX
• CIK: 1160308
• Web: www.savarapharma.com
• Phone: 512-614-1848
• Fax: 858-552-0876
• Employees: 70
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Savara: $10.25
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +142.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$118.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.28%
• Return on Assets: -68.95%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 10.13
• Quick Ratio: 10.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 4.22

Miscellaneous

• Outstanding Shares: 205,460,000
• Free Float: 194,571,000
• Market Cap: $867.04 million
• Optionable: Optionable
• Beta: 0.20